Case Report: QT Prolongation and Abortive Sudden Death Observed in an 85-Year-Old Female Patient With Advanced Lung Cancer Treated With Tyrosine Kinase Inhibitor Osimertinib

被引：10

作者：

Kondo, Moe ^{[1
]}

Kisanuki, Megumi ^{[1
]}

Kokawa, Yosuke ^{[1
]}

Gohara, Seiichiro ^{[1
]}

Kawano, Osamu ^{[1
]}

Kagiyama, Shuntaro ^{[1
]}

Maruyama, Toru ^{[2
]}

Odashiro, Keita ^{[1
]}

Maehara, Yoshihiko ^{[1
]}

机构：

[1] Kyushu Cent Hosp, Dept Internal Med, Div Cardiol, Fukuoka, Japan

[2] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Japan

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2021年 / 8卷

关键词：

cancer; herbal drug; osimertinib; QT prolongation; cardiooncology;

D O I：

10.3389/fcvm.2021.655808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiac arrest occurred in an 85-year-old female administered osimertinib for advanced lung cancer expressing epidermal growth factor receptor (EGFR) mutations. Electrocardiogram (ECG) recorded at recurrence of spontaneous circulation showed sinus rhythm associated with mild QT prolongation (QTc = 455 ms) to which silent myocardial ischemia and coadministration of itraconazole and herbal drug causing hypokalemia (2.1 mEq/L) may have contributed. Discontinuation of osimertinib, itraconazole and herbal drug, potassium supplementation and percutaneous coronary intervention alleviated QT prolongation (QTc = 432 ms). Osimertinib is the third-generation tyrosine kinase inhibitor lengthening QT interval, and careful monitoring of ECG, serum potassium and drugs coadministered during chemotherapy including osimertinib are highly required.

引用

页数：5

共 17 条

[1] A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin [J].

Bian, Shuang ;

Tang, Xiaomiao ;

Lei, Wei .

BMC PULMONARY MEDICINE, 2020, 20 (01)

[2] Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities [J].

Chaar, Maher ;

Kamta, Jeff ;

Ait-Oudhia, Sihem .

ONCOTARGETS AND THERAPY, 2018, 11 :6227-6237

[3] Risk Factors for Pseudoaldosteronism with Yokukansan Use: Analysis Using the Japanese Adverse Drug Report (JADER) Database [J].

Ishida, Tomoaki ;

Kawada, Kei ;

Morisawa, Shumpei ;

Jobu, Kohei ;

Morita, Yasuyo ;

Miyamura, Mitsuhiko .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2020, 43 (10) :1570-1576

[4] Open-loop, clockwise QT-RR hysteresis immediately before the onset of torsades de pointes in type 2 long QT syndrome [J].

Nakaji, Gen ;

Fujiwara, Masahiko ;

Fukata, Mitsuhiro ;

Yasuda, Shioto ;

Odashiro, Keita ;

Maruyama, Tom ;

Akashi, Koichi .

JOURNAL OF ELECTROCARDIOLOGY, 2010, 43 (03) :261-263

[5] Association Between QT-Interval Components and Sudden Cardiac Death The ARIC Study (Atherosclerosis Risk in Communities) [J].

O'Neal, Wesley T. ;

Singleton, Matthew J. ;

Roberts, Jason D. ;

Tereshchenko, Larisa G. ;

Sotoodehnia, Nona ;

Chen, Lin Y. ;

Marcus, Gregory M. ;

Soliman, Elsayed Z. .

CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2017, 10 (10)

[6] Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review [J].

Porta-Sanchez, Andreu ;

Gilbert, Cameron ;

Spears, Danna ;

Amir, Eitan ;

Chan, Joyce ;

Nanthakumar, Kumaraswamy ;

Thavendiranathan, Paaladinesh .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (12)

[7] Cardiovascular toxicity of PI3Kα inhibitors [J].

Sadasivan, Chandu ;

Zhabyeyev, Pavel ;

Labib, Dina ;

White, James A. ;

Paterson, D. Ian ;

Oudit, Gavin Y. .

CLINICAL SCIENCE, 2020, 134 (19) :2595-2622

[8] Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring [J].

Schiefer, Mart ;

Hendriks, Lizza E. L. ;

Trang Dinh ;

Lalji, Ulrich ;

Dingemans, Anne-Marie C. .

EUROPEAN JOURNAL OF CANCER, 2018, 91 :92-98

[9] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

[10] Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer [J].

Teisseyre, Andrzej ;

Palko-Labuz, Anna ;

Sroda-Pomianek, Kamila ;

Michalak, Krystyna .

FRONTIERS IN ONCOLOGY, 2019, 9

← 1 2 →